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Background: Significant heterogeneity of clinical presentation and disease progression exists 
within chronic obstructive pulmonary disease (COPD). Although forced expiratory volume in 
1 second (FEV1) inadequately describes this heterogeneity, a clear alternative has not emerged. 
This article discusses and refines the concept of phenotyping desaturators in COPD and shows 
a possible pattern which could be used as a framework for future research.
Recent findings: COPD is a complex condition with pulmonary and extrapulmonary mani-
festations. We suggest that COPD phenotypes should be associated with clinically meaningful 
outcomes. The innovation of COPD phenotyping is defined as COPD desaturators. Sleep-related 
hypoxemia and hypercapnia are well recognized in COPD and the development of systemic 
inflammation during sleep. These sleep-related changes predispose to nocturnal cardiac arrhyth-
mias, pulmonary hypertension, and possibly death, particularly during acute exacerbations.
Conclusion: A more focused definition makes possible a classification of patients into two 
distinct subgroups for both clinical and research purposes. Establishing a common language 
for future research will facilitate our understanding and management of such diseases. Even 
if different treatment strategies have different outcomes for these groups, we will have con-
firmation, or otherwise, of the clinical value of cluster analysis. This knowledge could lead to 
pharmacological treatment and other interventions directed to specific phenotypic groups.
Keywords: phenotypes, chronic obstructive pulmonary disease, desaturator, nocturnal 
  hypoxemia, systemic inflammation, intermittent hypoxia
Introduction
Chronic obstructive pulmonary disease (COPD) is defined as a “preventable” but 
treatable disease with significant extrapulmonary effects that may contribute to its 
severity in individual patients.1 However, COPD is a complex, multicomponent, 
heterogeneous disease, the clinical, functional and radiological presentation of which 
varies greatly from patient to patient, even though the degree of airflow limitation 
may be similar.1,2 The current classification of airways disorders is imprecise, with 
an overlap of phenotypes (eg, asthma, chronic bronchitis, and emphysema), resulting 
in difficulties in differentiating between these disorders.
The prevalence, distribution, and interrelationships of the main clinical and 
functional manifestations of the disease in a large, well-characterized, and controlled 
population of patients is lacking. Comorbidities such as chronic heart failure, cardio-
vascular disease, depression, diabetes, muscle wasting, weight loss, lung cancer, and 
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osteoporosis, are frequently found in patients with COPD, 
and are considered to be part of the commonly prevalent 
nonpulmonary sequelae of the disease.3,4 Sleep-disordered 
breathing and COPD are among the most common   pulmonary 
diseases.
Cluster analysis is a collection of methods for defining 
groups of individuals based on measured characteristics, 
so they can be grouped according to their differences (or 
similarities) into clusters. This paper focuses on COPD and 
nocturnal hypoxemia, aiming at defining, through cluster 
analysis, a pattern of clinical variables that differentiate 
desaturator from nondesaturator patients and at identifying 
daytime variables that are predictive of nocturnal desatura-
tion. This more focused description makes possible a clas-
sification of patients into distinct subgroups for both clinical 
and research purposes.
Systemic inflammation in COPD
Several studies have found markers of systemic inflamma-
tion, such as high-sensitivity C-reactive protein, to be higher 
in the blood of patients with COPD than in subjects without 
COPD.5,6 The question arises as to whether systemic inflam-
mation is the result of a local inflammation spillover into the 
systemic compartments or a systemic component of COPD 
not necessarily related to local inflammatory processes in 
the lung.7,8
As a point of interest, it should be noted that systemic 
inflammation has failed, so far, to show substantial correlations 
with airway obstruction,9,11 whereas at least some relationship 
has been reported between local inflammatory processes and 
airway obstruction.12,14 Markers of systemic inflammation 
have been shown to be elevated in the blood of patients 
with COPD when compared with control subjects without 
COPD. COPD is often accompanied by other chronic diseases 
associated with systemic inflammation, such as chronic 
heart failure, diabetes, and arteriosclerosis.15   Alternatively, 
increased blood levels of inflammatory mediators in patients 
may stem from extrapulmonary cells (circulating leukocytes, 
endothelium, or muscle cells). A particular problem in COPD 
patients with marked alveolar wall destruction is intermittent 
and continuous hypoxia. A significant inverse correlation 
between arterial oxygen tension (PaO2), circulating tumor 
necrosis factor alpha, and soluble tumor necrosis factor 
receptor levels has been reported in patients with COPD.16 
Similarly, a significant relationship between reduced oxygen 
delivery and tumor necrosis factor alpha levels in the 
peripheral circulation has been found, highlighting the role 
of nocturnal hypoxia in the tissue.17
It has been suggested that systemic inflammation may 
explain part of the heterogeneity of COPD phenotypes, 
such as loss of lean body mass and the higher prevalence 
of comorbid disorders, such as coronary heart disease, 
depression, and hypertension. Finally, this study reinforces 
the view that systemic inflammation is an important pheno-
typic feature of COPD.18 Future prospective studies should 
investigate whether these markers give important prognostic 
information in relation to disease progression and severity 
in COPD.
Sleep in patients with COPD
COPD alone can cause subjective and objective changes 
during sleep. When patients with chronic bronchitis or 
emphysema were surveyed across a broad range of symp-
toms, “sleep difficulties” were endorsed as occurring 
“almost always” or “always” in 43% of subjects (third 
most common, after dyspnea and fatigue).19 In addition to 
the diagnosis of COPD, the presence of COPD symptoms, 
such as cough, sputum production, and wheezing correlated 
strongly with difficulty in falling or staying asleep.20 Other 
investigations have objectively confirmed poor sleep qual-
ity, with decreased total sleep time and decreased sleep 
efficiency.21
A brief review of the normal changes in respiration that 
occur with sleep onset and the various sleep stages is useful 
for understanding the changes occurring during sleep in 
patients with COPD. In healthy subjects, minute ventila-
tion drops from wakefulness to non-rapid eye movement 
(non-REM) sleep, and drops further during REM sleep 
(about 15% compared with the awake value).22 Most of 
the drop in minute ventilation is due to a decrease in tidal 
volume not fully compensated by a concomitant increase 
in respiratory rate. There is a blunted ventilatory response 
to hypoxia and hypercapnia, again with the greatest 
changes during REM sleep.23 Sleep-related hypoventila-
tion has been demonstrated in COPD, particularly dur-
ing REM sleep, with associated oxygen desaturation.24 
Nocturnal oxygen desaturation in COPD is likely to be 
the consequence of the combined effects of physiological 
hypoventilation during sleep. However, there is evidence 
that some patients with awake PaO2 levels in the mildly 
hypoxemic range can also develop clinically significant 
nocturnal oxygen desaturation, which may predispose to 
pulmonary hypertension.25 Finally, possible mechanisms 
responsible for this reduction include respiratory muscle 
hypotonia, cephalic displacement of the diaphragm, and a 
decrease in lung compliance.26
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Mechanisms of sleep-related 
breathing disturbances in COPD
Sleep-related hypoventilation has been demonstrated in 
COPD, with associated oxygen desaturation particularly 
during REM sleep.27 There is a close relationship between 
the awake PaO2 and nocturnal oxygen saturation levels,28 
although hypercapnia is associated with more pronounced 
nocturnal oxygen desaturation than normocapnia for any 
given level of waking oxygen saturation level.29
Nocturnal hypoxemia is defined as an oxygen satura-
tion level #90% for at least 5 minutes, with a nadir oxygen 
saturation level of #85%. Time in bed is defined as the time 
from the start to end of the recording. The percentage of 
total recording time is defined as time spent in bed – sleep 
latency + intrasleep wakefulness. The total recording 
time spent in bed with an oxygen saturation level #90% 
is defined as the T90. The minimal total recording time 
required for satisfactory analysis of nocturnal recordings 
is 2 hours. In one study, COPD patients with a T90 $ 30% 
and a nadir oxygen saturation level of 85% were defined 
as desaturators and the others as nondesaturators.30 COPD 
desaturator patients may be identified by a clinical pattern 
of variables rather than by T90 alone, ie,T90, mean pulmonary 
artery pressure, and arterial carbon dioxide tension values, 
with the latter two variables being predictors of severity of 
nocturnal desaturation. Alveolar hypoventilation probably 
accounts for most of the oxygen desaturation. Becker et al31 
measured minute ventilation during wakefulness, non-REM 
sleep, and REM sleep in normal subjects and in patients 
with COPD. The greater drop seen in minute ventilation 
in subjects with COPD may reflect increased dependence 
on accessory muscles that become hypotonic during sleep, 
particularly during REM sleep. An alternative explanation 
comes from the work of O’Donoghue et al32 who found an 
even greater drop in minute ventilation during non-REM 
sleep in hypercapnic COPD patients.
Consequences of nocturnal oxygen 
desaturation in COPD
The exact prevalence of pulmonary hypertension in patients 
with COPD is unclear.33 Pulmonary hypertension is a 
complication of advanced COPD observed in patients who 
show severe longstanding hypoxemia. Even if pulmonary 
  hypertension is generally mild to moderate in most COPD 
patients, it may worsen markedly during acute exacerba-
tions, sleep, and exercise, and these acute increases in 
pulmonary hypertension could facilitate the development 
of right heart failure. Diagnosis of pulmonary hypertension   
in COPD patients is difficult. The published studies dif-
fer not only in their definitions but also for conditions in 
which pulmonary hypertension has been reported (ie, rest, 
  exercise, and   exacerbation). According to the European 
Society   Cardiology and European Respiratory Society,34 
pulmonary hypertension is defined as an increase in mean 
pulmonary artery pressure $25 mmHg at rest as assessed 
by right heart catheterization. The definition of pulmonary 
hypertension on exercise as a pulmonary artery pressure 
$30 mmHg assessed by right heart catheterization is not 
supported by the published data, and healthy individuals can 
reach much higher values.
The incidence of pulmonary hypertension in COPD 
patients has been evaluated by Kessler et al,35 who performed 
a longitudinal study in 131 patients with COPD with serial 
right heart catheterization at baseline and then at follow-up 
(mean 6.8 ± 2.9 years). All subjects had normal mean pul-
monary artery pressure at rest (#20 mmHg). They were 
divided into two groups according to the presence or absence 
of elevated mean pulmonary artery pressure with exercise 
($30 mmHg), and 25% of patients developed pulmonary 
hypertension on follow-up that was mild by hemodynamic 
criteria (mean pulmonary artery pressure 26.8 ± 6.6 mmHg). 
Subjects who showed elevated pulmonary hypertension with 
exercise were more likely to exhibit resting mean pulmonary 
artery pressure elevation at follow-up. The annual rate of 
progression was +0.4 mmHg.
Nocturnal oxygen desaturation seems to contribute to the 
development of pulmonary hypertension, even in the absence 
of significant awake hypoxemia.36 REM-associated falls in 
oxygen saturation levels are associated with increases in 
pulmonary artery pressure during sleep that can be reversed 
by supplemental oxygen, although most COPD patients 
with sustained pulmonary hypertension are also hypoxemic 
during the daytime. Various arrhythmias have also been 
reported during episodes of nocturnal desaturation.37 These 
observations might help to explain why nocturnal oxygen 
desaturation is a marker of increased mortality, and why 
COPD patients are reported to die more frequently than 
expected at night.38
Tissue hypoxia is another mechanism that can contribute 
to systemic inflammation in COPD. In one clinical study19 
it was shown that tumor necrosis factor alpha and its recep-
tor levels were significantly higher in patients with COPD, 
and were correlated significantly with severity of arterial 
hypoxemia. These results suggest that arterial hypoxemia 
in COPD is associated with activation of the tumor necrosis 
factor alpha system in vivo.
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The systemic effects of inflammation may   contribute 
  significantly to not only the respiratory abnormalities, 
  symptoms, and functional impairment (eg, exercise 
  intolerance) associated with COPD but also to the marked 
changes in vasomotor and endothelial function seen in 
chronic pulmonary vascular disease.39 The nocturnal desat-
uration-reoxygenation sequence is a typical pattern coupled 
with the majority of respiratory events. This sequence, 
defining intermittent hypoxia, leads to oxidative stress, with 
production of reactive oxygen species.40 Hypoxia-induced 
pulmonary vasoconstriction is a protective response to 
keep the ventilation-perfusion ratio at an optimum level 
by shunting blood away from hypoxemic areas. The tradi-
tional hypoxic model of pulmonary hypertension is based 
on the hypothesis that chronic hypoxia initiates vascular 
remodeling, leading to permanent changes in the pulmonary 
vasculature. Studies performed in vitro have elucidated the 
mechanisms underlying hypoxia-driven vascular changes. 
Barbera et al41 evaluated COPD patients undergoing lung 
resection and demonstrated that vascular changes contribute 
to vascular remodeling and putatively may have an effect on 
the vascular dynamics leading to pulmonary hypertension. 
Nocturnal hypoxia may induce endothelial cells to release 
cytokines, leading to cellular hypertrophy in the vessel wall 
and an increase in the extracellular matrix. In conclusion, the 
nocturnal hypoxic insult occurring during sleep-disordered 
breathing may contribute to chronic vascular remodeling, 
causing vascular endothelial damage and dysfunction, and 
increasing the risk of pulmonary hypertension in COPD.42
Use of cluster analysis to define 
potential COPD phenotypes
Traditionally, on the basis of specific clinical, functional, 
and radiological features, patients with COPD used to be 
classified into different biotypes, ie, the “blue bloater,” in 
association with predominantly chronic bronchitis, and the 
“pink puffer,” identified as predominantly emphysema.43 
However, these are only two extreme phenotypes among 
a broader spectrum of clinical presentations in COPD. 
  Accordingly, we propose a variation on the traditional 
definition of a phenotype, ie, a single disease attribute or 
a combination of disease attributes describing differences 
between individuals with COPD as they relate to clinically 
meaningful outcomes. It is proposed that phenotypes in 
COPD should have real predictive value. Studies carried out 
in recent years have revealed that patients with the same stage 
of disease may show different pathological changes,44,45 and 
classic COPD phenotypes clearly differ from these based 
on severity of emphysema as assessed by high-resolution 
computed tomography scanning.46
The goal of phenotyping is to identify patient groups 
with unique prognostic or therapeutic characteristics. 
  However, significant variation and confusion surrounds the 
use of the term “phenotype” in COPD. Phenotype classi-
cally refers to any observable characteristic of an organism, 
and until now multiple disease characteristics have been 
termed COPD phenotypes.47 Evidence has shown that 
different COPD phenotypes may be significantly associ-
ated with differences in body mass index, health-related 
quality of life,43 small airways obstruction,45 and systemic 
inflammation.48
Cluster analysis is a collection of methods for defining 
groups of individuals based on measured characteristics, so 
that they can be grouped according to their similarities or 
differences into clusters.49,51 Groupings are created so that 
the degree of association is strong between members of 
the same cluster and weak between members of different 
clusters.52 Cluster analysis is distinct from other ways of 
trying to understand multivariate data, including principal 
component and factor analysis, discriminant analysis, and 
multivariate regression. The clinical relevance of cluster 
analysis will depend on developing diagnostic criteria to 
allow new individuals to be allocated into groups based on 
the identified clusters.
More recent work,53 including that of Burgel et al,54 has 
used cluster analysis to characterize different types of air-
ways disorder. The main conclusion from Burgel et al is that 
COPD patients with similar airflow obstruction can belong 
to different phenotypes, and have different symptoms (dys-
pnea) and outcomes (number of exacerbations and predicted 
mortality). At a more specific level, it is worthy of note that 
both Wardlaw et al52 and Weatherall et al53 have identified 
a cluster characterized by severe and markedly variable 
airflow obstruction with features of atopic asthma, chronic 
bronchitis, and emphysema. Patients in this phenotypic group 
would be unlikely to meet the inclusion criteria of the major 
randomized, controlled trials of either asthma55 or COPD.56 
The identification of COPD phenotypes will require an 
iterative validation process in which candidate phenotypes 
are identified before their relevance to clinical outcome is 
determined.
Classification of COPD desaturator 
phenotypes using cluster analysis
COPD patients can be classified as desaturators or nonde-
saturators based on a T90 of 30% on polygraphic recording. 
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One study29 of 51 consecutive COPD outpatients with 
mild daytime hypoxemia (PaO2 60–70 mmHg) identified 
a pattern of daytime clinical variables that distinguished 
desaturators from nondesaturators by using cluster analysis 
(see Table 1).
Considering all patients, T90, mean pulmonary artery 
pressure at rest, PaCO2, nadir oxygen saturation level, 
mean nocturnal oxygen saturation level, predicted total 
lung capacity, baseline oxygen saturation level awake, pre-
dicted vital capacity, and body mass index had a bimodal 
distribution. The variables examined in the study did not 
differ between men and women. Rather than using T90 
alone, desaturator patients may be identified by a pattern 
of T90 (30.08%–45.1%, P = 0.0001) mean pulmonary 
artery pressure (33.1 ± 0.7 mmHg, P = 0.0006), and PaCO2 
(35.0–57.9 mmHg, P = 0.0005) values, with the latter two 
variables being predictors of severity of nocturnal desatura-
tion (see Table 2).
A hierarchical cluster analysis has been performed 
using these three variables, showing the highest correlation 
by least-squares multiple linear regression (ie, T90, mean 
pulmonary artery pressure, and PaCO2). First, we identified 
two major clusters of patients designated as desaturator and 
nondesaturators, their mean values coinciding with those of 
the cluster centroid. In any event, a T90 cutoff value does not 
appear to describe a cluster of desaturator patients adequately 
or to assess correctly the severity of nocturnal desaturation. 
Moreover, cluster analysis identifies subgroups of desaturator 
and nondesaturator patients who differed in degree of disease 
severity.
The finding that T90, mean pulmonary artery pressure, 
and PaCO2 were required to identify desaturator and nonde-
saturator patients by cluster analysis demonstrates that these 
variables play a predictive role. Desaturator patients have 
higher values for mean pulmonary artery pressure, PaCO2 
and T90 than nondesaturator patients. Interestingly, cluster 
analysis has identified subpopulations of desaturator and non-
desaturator patients, ie, two desaturator subgroups divided 
according to mean pulmonary artery pressure values, and 
two nondesaturator subgroups divided according to PaCO2 
values. By reducing the distance between the elements of 
clusters, more clusters (or rather subdivisions) of desaturator 
and nondesaturator groups were obtained.30
Two subgroups, accounting for 76% of patients, were 
identified in the nondesaturator group, with the remain-
ing 24% (six of 25 patients) being comprised of scattered 
individual patients. The ND1 nondesaturator subgroup com-
prised five of 25 patients (20%; one of five women [20% of 
the subgroup]; four of five men [80% of the subgroup]). The 
centroids were as follows: T90, 22.0%; mean pulmonary artery 
pressure, 19.2 mmHg; and PaCO2, 46.5 mmHg. The ND2 
nondesaturator subgroup comprised 14 of 25 patients (56%; 
eight of 14 women [57.1% of the subgroup]; six of 14 men 
[42.9% of the subgroup]). The centroids were as follows: 
T90, 20.1%; mean pulmonary artery pressure, 18.5 mmHg; 
and PaCO2, 33.3 mmHg. Similarly, the desaturator group 
Table 1 Variable mean values ± standard errors of the mean and range of both desaturator and nondesaturator groups of COPD 
patient phenotypes
Variables Group D (n = 26) Group ND (n = 25)
Mean ± SD Median Range Mean ± SD Median Range
Age (years)   70.5 ± 3.9 71.0 61–78 68.6 ± 3.9 70.0 59–73
BMI kg/m2   31.3 ± 2.1 32.0 26.6–35.0 29.1 ± 3.1 29.0 23.8–36.9
PaO2 mmHg   63.5 ± 3.4 63.1 60.0–69.2 64.9 ± 3.4 65.1 60.0–69.7
PaCO2 mmHg   50.0 ± 4.2 50.7 35.1–57.9 38.0 ± 6.9 34.3 30.2–50.9
Baseline SaO2 awake (%)   89.9 ± 1.9 90.0 85.0–93.0 91.3 ± 1.40 91.0 89.0–93.0
FEV1 (% predicted)   52.2 ± 9.6 56.8 35.2–65.5 53.8 ± 12.7 58.1 33.5–68.9
FEV1/FVC ratio   40.1 ± 3.4 41.2 34.6–46.8 34.9 ± 2.2 34.6 31.1–38.9
TLC (% predicted) 107.4 ± 7.9 105.7 98.5–121.5 98.0 ± 6.6 98.7 87.3–115.6
Vital capacity (% predicted)   84.7 ± 6.8 85.9 68.1–98.7 78.1 ± 9.8 80.6 62.3–98.8
MPAP at rest (mmHg)   33.1 ± 3.6 32.0 28.0–40.0 19.8 ± 4.3 19.0 16.0–37.0
Mean nocturnal SaO2 (%)   86.6 ± 4.1 87.8 75.1–92.3 91.6 ± 2.1 92.1 85.5–94.7
Nadir SaO2 (%)   78.4 ± 7.2 79.3 54.3–88.6 86.4 ± 2.3 87.1 79.3–89.2
T90 (%)   37.2 ± 3.5 37.7 30.8–45.5 21.2 ± 3.6 22.1 15.2–28.4
AHI, per hour of sleep   2.9 ± 0.8 2.8 1.2–4.5   2.7 ± 0.7 2.8 1.1–4.1
ESS score   3.9 ± 1.2 4.0 2.0–6.0 3.76 ± 1.9 4.0 0–7.0
Abbreviations: AHI, apnea-hypopnea index; BMI, body mass index; ESS, Epworth Sleepiness Scale; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
MPAP, mean pulmonary artery pressure; TLC, total lung capacity; T90, recording time spent in bed with an oxygen saturation level #90%; PaO2, arterial oxygen tension; PaCO2, 
arterial carbon dioxide tension; SaO2 oxygen saturation; COPD, chronic obstructive pulmonary disease; D, desaturator; ND, nondesaturator; SD, standard deviation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
555
COPD desaturator phenotypesInternational Journal of COPD 2011:6
was divided into two subgroups accounting for 88.4% of 
desaturator patients, with the remaining 11.5% (three of 
26 patients) consisting of scattered individual patients. The 
D1 desaturator subgroup comprised seven of 26 patients 
(26.9%, three of seven women [42.8% of the subgroup]; 
four of seven men [57.2% of the subgroup]). The cen-
troids were as follows: T90, 38.8%; mean pulmonary artery 
pressure, 38.0 mmHg; and PaCO2, 52.0 mmHg. The D2 
desaturator subgroup comprised 16 of 26 patients (61.5%; 
five of 16 women [31.2% of the subgroup]; 11 of 16 men 
[68.8% of the subgroup]) The centroids were as follows: 
T90 37.0%; mean pulmonary artery pressure, 31.5 mmHg; 
and PaCO2 49.9 mmHg. These data show that PaCO2 was 
higher in ND1 patients than in ND2 patients, and that mean 
pulmonary artery pressure was higher in D1 patients than 
in D2 patients.
Finally, cluster analysis showed that most of the subjects 
with higher PaCO2 values were men in the small ND1 sub-
group. This applies also to the D2 subgroup, but the men in 
this subgroup had lower levels of mean pulmonary artery 
pressure levels than the women.
Further studies are required to understand the importance 
of these findings. They provide a naturalistic classification 
that, if confirmed in other studies, could be developed into a 
modified taxonomy for disorders of sleep-related breathing 
disturbances in COPD. In conclusion,30 this cluster analysis 
showed that clustered COPD desaturator patients can be 
identified not by T90 value alone, but by a pattern of T90, 
mean pulmonary artery pressure, and PaCO2 values, and 
that the latter two variables are predictors of the severity of 
nocturnal desaturation.
Awake desaturator patients have lower PaO2 and higher 
PaCO2 values than awake nondesaturator patients.57 Moreover, 
daytime hypercapnia is a risk factor for nocturnal hypoxemia 
in COPD patients with mild daytime hypoxemia.58
The degree of airways obstruction in COPD patients, 
as measured by forced expiratory volume in 1 second 
(FEV1)/forced vital capacity, can correlate with the risk 
of prolonged hypoxemia,59 which appears to increase the 
morbidity and mortality risk in these patients, although the 
exact mechanism(s) that account for this increased risk are 
not well understood. The increased risk of death may be due 
to more prolonged hypoxia, although night-time hypercapnia 
is probably also greater. There is also increasing evidence 
that COPD has systemic consequences. Inflammation is 
caused via various mediators (tumor necrosis factor alpha, 
interleukin-6, and interleukin-8), in addition to the oxidative 
stress. The review by McNicholas shows how the disease acts 
through similar pathways to cause cardiovascular disease.60 
Another intriguing possibility mentioned in that review is 
that nocturnal desaturation in COPD may contribute to an 
increased incidence of COPD exacerbations, which may 
accelerate the decline in lung function and be associated 
with greater mortality.61,62
Further cluster analyses, both population-based and 
clinic-based, will contribute to greater understanding of the 
true patterns of airway disorders. The clinical application of 
cluster analysis will depend on developing diagnostic criteria 
to allow new individuals to be allocated to groups based on 
identified clusters.
Diagnosis
The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD)1 guidelines suggest that patients with relatively 
mild COPD and evidence of pulmonary hypertension 
and diurnal hypercapnia should be referred for overnight 
testing. This recommendation reflects data collected by 
Chaouat et al66 and Toraldo et al30 and emphasized by 
Kessler,35 ie, in all COPD patients with obesity, higher 
diurnal PaCO2 reflects increased muscle load in those 
with both increased upper and lower airway resistance. 
It is necessary to perform the   following examinations:30 
static lung volumes measured by body plethysmography 
and dynamic lung volumes by mass flow sensors in seated 
patients according to standard   procedures; arterial blood 
gases measured at the radial artery using   microelectrodes 
in seated patients   spontaneously   breathing air; resting mean 
daytime pulmonary artery pressure   measured by color 
Table 2 Variables describing desaturator COPD patient phenotypes using cluster analysis
Variables Group D Group ND P value
Mean ± SE Range Mean ± SE Range
T90 (%) 37.2 ± 0.7 30.8–45.5 21.2 ± 3.6 15.2–28.4 0.0001
MPAP at rest, mmHg 33.1 ± 0.7 28.0–40.0 19.8 ± 4.3 16.0–37.0 0.0006
PaCO2, mmHg 50.0 ± 0.8 35.1–57.9 38.0 ± 6.9 30.2–50.9 0.0005
Abbreviations: SE, standard error of the mean; MPAP, mean pulmonary artery pressure; PaCO2, arterial carbon dioxide tension; COPD, chronic obstructive pulmonary 
disease; D, desaturator; ND, nondesaturator.
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Doppler echocardiography; and nocturnal desaturation 
evaluated by polygraphic recording of oxygen saturation, 
snoring, air flow, thoracic and abdominal respiratory 
movements, heart rate, including an electrocardiogram in 
real-time mode; and body position.
In our research, patients with a history of loud snoring and 
excessive daytime sleepiness, as evaluated by the Epworth 
Sleepiness Scale (range 0–10) and with an apnea-hypopnea 
index $5 per hour were excluded because of suspected 
obstructive sleep apnea syndrome. We also excluded patients 
in whom mean pulmonary artery pressure could not be evalu-
ated by color Doppler echocardiography. Finally, quantitative 
assessment of emphysema by computed tomography scan-
ning offers an objective measure of parenchymal disease that 
correlates well with histopathologic findings and is predictive 
of the degree of expiratory airflow obstruction. Objective 
measures of proximal airway wall thickening obtained via 
computed tomography are inversely correlated with lung 
function and relate to burden of small airway disease and 
exacerbation frequency.
Treatment
Management options for patients with sleep-related respira-
tory disturbances include general measures, such as optimiz-
ing therapy for the underlying condition and supplemental 
oxygen, in addition to pharmacological therapy. We propose 
that COPD phenotypes should be associated with clinically 
meaningful outcomes. Such a more focused definition makes 
possible a classification of patients into distinct prognostic 
and therapeutic subgroups for both clinical and research 
purposes. The goal of treatment is to maintain adequate 
oxygenation at all times and to prevent sleep-disordered 
breathing. Supplemental oxygen is the mainstay of treatment 
for those with daytime and nocturnal hypoxemia, and has 
been shown to reduce overall mortality if used for more than 
18 hours per day, including during sleep.63,64
It may be that COPD patients with hypoxemia are at 
increased risk of mortality only during sleep, compared with 
those who are not, although this finding is only based on a 
single study of retrospective data.65 Again, correction of noc-
turnal hypoxemia alone (in patients with daytime normoxia) 
does not seem to improve pulmonary hemodynamics or 
mortality to a significant extent,66,67 although it may improve 
sleep quality and is frequently prescribed.68
A Cochrane analysis69 determined the effect of   domiciliary 
oxygen on survival in COPD and identified six relevant ran-
domized controlled trials. There was no effect on survival 
during 3 years of follow-up in patients with mild to   moderate 
hypoxemia and those with only arterial desaturation at 
night. Home oxygen improved survival only in patients with 
PaO2 # 60 mmHg.
Controversy exists as to whether continuous positive 
airway pressure (CPAP) therapy improves daytime lung 
function in patients with stable COPD. At least in an animal 
model, upper airways irritation increased lower airway resis-
tance, so, in theory, correction of repetitive airway collapse 
might improve pulmonary function.70 Others have postu-
lated that offloading the respiratory muscles could decrease 
hypoventilation, oxygen consumption, and carbon dioxide 
production by the respiratory muscles. These muscles may 
be rested by CPAP, given that it prevents the increase in 
upper airway resistance occurring during sleep. Alternatively, 
CPAP may offset intrinsic positive end-expiratory pressure 
in severe COPD. Mezzanotte et al used CPAP for 1–3 weeks 
in eight patients with COPD and assessed inspiratory force 
and endurance. They found significant improvements in 
maximum inspiratory force and performance on a 12-minute 
walk test.71 Improvements have also been observed in day-
time oxygenation and hypercapnia.72,73
Long-term nocturnal noninvasive ventilation can also be 
considered in COPD patients with chronic respiratory failure, 
with improvements in gas exchange during wakefulness hav-
ing been reported,74 in addition to improvements in respiratory 
muscle strength and endurance.75 Sleep quality and diurnal 
PaO2 and PaCO2 levels are better with noninvasive ventilation 
plus supplemental oxygen than with supplemental oxygen 
alone.76 There has been considerable interest in the use of non-
invasive ventilation in stable hypercapnic COPD, with mul-
tiple studies and inconsistent results over the years.77 Several 
mechanisms are likely to play a role in these improvements, 
including rest of chronically fatigued respiratory muscles, 
thereby improving daytime respiratory muscle function.78
Two recent studies warrant attention. The first was a ran-
domized controlled trial of noninvasive ventilation in patients 
with stable hypercapnic COPD by McEvoy et al, which showed 
significant improvement in adjusted mortality.79 There was little 
or no change in pulmonary function or daytime blood gases. 
The improvement in mortality using noninvasive ventilation 
was associated with a worse quality of life, which tempers 
enthusiasm for this approach. A second report by Windisch et al 
reported a reduction in mortality with noninvasive ventilation, 
although only used   historical controls. However, these authors 
used what they called “high-intensity noninvasive ventila-
tion,” with a very high driving pressure (average inspiratory 
pressure 28 cm H2O, average expiratory pressure 5 cm H2O) 
and a high   respiratory rate (about 21 breaths per minute). With 
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those settings,   requiring hospital acclimatization, there were 
improvements in spirometry and blood gas abnormalities.80
Weight loss
Weight loss can clearly be beneficial in obese COPD patients 
with a desaturator phenotype.81 However, in COPD, weight 
loss has generally been associated with increased mortality, 
because cachexia sets in with increasing disease   severity. 
Thus, there are no data to recommend weight loss as a 
therapeutic option in those with the COPD desaturator phe-
notype, although it seems reasonable that those with less 
severe COPD would benefit from dietary and respiratory 
rehabilitation.
Bronchodilators and corticosteroids
Treatment of the underlying obstructive lung disease is 
helpful in preventing or ameliorating nocturnal oxygen 
desaturation in patients with COPD. Data exist for the 
cholinergic bronchodilators, ipratropium and tiotropium. 
Martin et al studied the effect of ipratropium inhaled four 
times a day in 36 patients with moderate to severe COPD 
(FEV1 # 65% predicted).82 After 4 weeks, nocturnal 
oxygen saturation improved, subjective sleep quality was 
better, and there was an increase in total REM sleep time. 
Tiotropium also improved nocturnal oxygen saturation, 
although sleep quality was not affected.83 A recent study 
with aclidinium bromide, a novel long-acting antimuscarinic 
drug,   investigated its potential effects on night-time symp-
toms in COPD. This study showed that the improvement 
in lung function obtained by administration of aclidinium 
bromide 400 mg twice daily translated into symptomatic 
benefits in COPD patients, especially during sleep and 
in the early morning.84 Long-acting β-agonists, such as 
salmeterol, show similar benefits.85 Oral steroid therapy in 
stable COPD improves nocturnal oxygen desaturation and 
increases total sleep time.86 Although there are no relevant 
data, we might expect a similar improvement with inhaled 
corticosteroids. Taken together, the data suggest that treat-
ment of COPD with or without hypercapnia will ameliorate 
nocturnal oxygen desaturation, and may decrease the need 
for supplemental oxygen as well as noninvasive ventilation. 
In Table 3, we outline some suggested management options 
for COPD patients with the desaturator phenotype who have 
sleep-related hypoxemia and/or hypercapnia.
Conclusion and future perspectives
Cluster analysis may prove useful in COPD phenotyping. 
Although the goal of cluster analysis is to reduce the number 
of observations or cases by grouping them into a smaller 
set of clusters, the goal of factor analysis is to reduce the 
number of variables by grouping them into a smaller set of 
factors. However, these types of analyses would still require 
longitudinal validation to determine how such clustered 
subjects differ in terms of important clinical outcomes. In 
addition, such analyses may or may not ultimately be useful 
in defining specific biologic pathways or therapies.
From a practical standpoint, validation of phenotypes in 
COPD will require longitudinal data collection in carefully 
characterized patient populations. Studies such as ECLIPSE 
(Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints), that are systematically gathering 
  clinical, physiological, radiological, biological, and genetic 
data on COPD subjects, will aid in this regard.87
Our study, albeit in only 51 patients, describes a statistical 
methodology allowing the identification of clinical COPD 
desaturator phenotypes. This study shows that desaturator 
Table 3 Management options for chronic obstructive pulmonary disease desaturator phenotype patients with sleep-related hypoxemia 
and/or hypercapnia
Optimize overall therapy of COPD
Prompt therapy of infective exacerbations
Supplemental oxygen therapy $2 L/minute when indicated (long-term oxygen therapy)
Noninvasive positive pressure ventilation particularly during acute exacerbations
Noninvasive positive pressure ventilation if PaCO2 50%–54% with hospitalization related to recurrent episodes of hypercapnic respiratory failure  
($2 in a 12-month period)
Noninvasive positive pressure ventilation if PaCO2 50%–54% with nocturnal desaturation (SaO2 # 88% for five continuous minutes while receiving 
oxygen therapy $2 L/minute)
Pharmacological therapy and bronchodilators, usually salmeterol, and particularly anticholinergics (ipratropium, tiotropium, and aclidinium bromide)
Theophylline
Multichannel sleep study to exclude associated OSA syndrome if clinically indicated
CPAP/BiPAP if “overlap syndrome” (COPD and OSA)
Abbreviations: CPAP, continuous positive airways pressure; PaCO2, arterial carbon dioxide tension; OSA, obstructive sleep apnea; COPD, chronic obstructive pulmonary 
disease; BiPAP, bilevel positive airway pressure.
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patients can be identified not by their T90 value alone but 
by a pattern of T90, mean pulmonary artery pressure, and 
PaCO2 values, and that the latter two variables are predictors 
of the severity of nocturnal desaturation. In any event, a T90 
cutoff value does not appear to describe desaturator patients 
adequately or to assess the severity of nocturnal desaturation 
correctly. Moreover, cluster analysis identified subgroups of 
desaturator and nondesaturator patients who differ in their 
degree of disease severity.
We propose that dissemination of this original approach 
could result in better phenotypic characterization, which may 
prove useful in both clinical practice and in clinical trials. 
We further propose that data from large clinical trials should 
be reanalyzed using this methodology for classification of 
patients according to their clinical characteristics at study 
entry. These preliminary data would provide a clear rationale 
for further clinical studies. The priority would then be to 
determine whether the phenotypes vary in their response to 
different pharmacological treatments. This knowledge could 
lead to treatment specifically targeted at defined phenotypic 
groups, rather than asthma or COPD in general, which is the 
current management approach. Ultimately, whether differ-
ent treatment strategies would provide different outcomes 
for these groups will confirm or refute the clinical value 
of cluster analysis. This knowledge could lead to different 
pharmacological treatments and other interventions directed 
at specific phenotypic groups.88 We consider that achieving 
this goal is worthy of the research endeavor.
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